Mitraclip presents Abbott upside regardless of suit result: Morgan Stanley

Morgan Stanley analyst David Lewis noted that Abbott (ABT) filed a complaint in Delaware and various jurisdictions outside of the U.S. alleging Edwards’ (EW) Pascal device infringes on Mitraclip’s intellectual property. While stating that it is currently challenging to weigh in on the probability or likelihood of success, Lewis said he believes his estimates for Mitracllip growth in 2019 are likely conservative and that he sees it as a driver of upside to Abbott growth regardless of a potential injunction. It is reasonable to assume Edwards developed Pascal in full awareness of Mitraclip’s patent portfolio, said Lewis, who added that “Pascal is the second most important catalyst this year from a sentiment perspective, but less of a contributor to topline growth” for Edwards.

https://thefly.com/landingPageNews.php?id=2855011